We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Hepregen Launches First Human HepatoPac™ Assay Kit
Product News

Hepregen Launches First Human HepatoPac™ Assay Kit

Hepregen Launches First Human HepatoPac™ Assay Kit
Product News

Hepregen Launches First Human HepatoPac™ Assay Kit


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Hepregen Launches First Human HepatoPac™ Assay Kit"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Hepregen Corporation has announced the commercial launch of the Company’s first HepatoPac™ kit designed specifically for use in evaluating metabolic turnover of chemicals in the human liver.

The kit contains one or more standard 96-well tissue culture plates featuring specially configured micro-patterned human liver cells co-cultured with stromal cells. The liver cells (hepatocytes) on these plates remain metabolically active for up to 35 days.

Using this plug-in-ready kit, industrial product developers can accurately evaluate metabolic turnover of chemicals regardless of whether they are rapidly or very slowly metabolized by the liver.

Jack McGeehan, Hepregen’s Vice President of Operations, stated, “The launch of this specially configured product so soon after the recent launch of the Company’s monkey HepatoPac™ kit for metabolite identification and profiling demonstrates the flexibility of Hepregen’s platform technology. This product launch provides another demonstration of our ability to rapidly develop and launch new application-directed products.”

Dr. Vincent Zurawski, Hepregen’s Chief Executive Officer added, “During the product development process, data generated from this new HepatoPac™ kit was used to predict drug clearance from the circulation with a high degree of in vitro/in vivo correlation when compared to clinical findings.”

Dr. Zurawski also stated, “The launch of this new kit demonstrates Hepregen’s commitment to providing its customers with unique problem-solving tools. The launch adds another product to the Company’s portfolio, which includes human, rat, monkey, human triple-donor and rat-human HepatoPac™ application-directed kits for metabolite identification and profiling.”

Advertisement